Another phase I trial of autologous T cell therapy for patients with ROR1+ triple negative breast cancer and ROR1+ non-small cell lung cancer (NCT02706392) assessed the safety profile in six patients, and no DLT was observed. The gene discussed is ROR1; the disease is triple-negative breast carcinoma.